Science Explorer Interactive view Map
Company · Tokyo · Japan

Oncolys BioPharma (Japan)

oncolys.com/enROR OpenAlex
Research works
90
▲ 21% vs 2013–17
Citations
1.7k
19.1 per fractional work
Top-10% rate
20.3%
record average 16.5%
Open access
45%
world 28%

Not ranked overall: Oncolys BioPharma (Japan) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.13× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 11.26× its world share, 8 worksBiochemistry, Geneti…Immunology and Microbiology: 5.73× its world share, 1 worksImmunology and Micro…Engineering: 0.12× its world share, 0 worksEngineeringMaterials Science: 0.35× its world share, 0 worksMaterials ScienceMedicine: 1.59× its world share, 4 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 11.3×. Every wedge is a field page.

Which keywords describe research at Oncolys BioPharma (Japan)?

By fractional works in all years, weighted toward what it does more of than the world: Gene Therapy, Immunotherapy, Tumor Regression, Genomic Integration, Tumor Targeting, AAV, Viral Vectors and Arginine Deprivation.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Gene Therapy40▲ 168×3 topics
  2. Immunotherapy26▲ 45×8 topics
  3. Tumor Regression20▲ 259×2 topics
  4. Genomic Integration19▲ 204×2 topics
  5. Tumor Targeting19▲ 159×3 topics
  6. AAV19▲ 319×1 topic
  7. Viral Vectors19▲ 319×1 topic
  8. Arginine Deprivation17▲ 428×1 topic
  9. Bacterial Therapy17▲ 428×1 topic
  10. Tumor Microenvironment5▲ 15×5 topics
  11. Gene Silencing5▲ 43×2 topics
  12. RNA Interference5▲ 45×1 topic
  13. siRNA Delivery5▲ 67×1 topic
  14. Cancer Immunotherapy4▲ 35×2 topics
  15. Inflammation4▲ 2.0×17 topics
  16. Oxidative Stress4▲ 2.5×19 topics
  17. Chemotherapy4▲ 6.1×9 topics
  18. CAR T Cells4▲ 89×1 topic
  19. Chimeric Antigen Receptor4▲ 89×1 topic
  20. Nanoparticles3▲ 2.8×5 topics
  21. Drug Resistance3▲ 11×2 topics
  22. Epithelial-Mesenchymal Transition3▲ 37×2 topics
  23. Tumor Metastasis3▲ 53×2 topics
  24. Cancer Stem Cells3▲ 72×1 topic
  25. Stem Cell Niches3▲ 72×1 topic
  26. Reactive Oxygen Species3▲ 6.0×3 topics
  27. Neoadjuvant Therapy2▲ 12×3 topics
  28. Pancreatic Cancer2▲ 22×1 topic
  29. Photodynamic Therapy2▲ 16×2 topics
  30. Surgical Complications2▲ 36×1 topic
  31. Biomarkers2▲ 3.7×7 topics
  32. Apoptosis2▲ 5.3×7 topics
  33. Fluorescence Imaging2▲ 19×1 topic
  34. HIF-12▲ 29×1 topic
  35. Photothermal Therapy2▲ 25×1 topic
  36. Warburg Effect2▲ 29×1 topic
  37. Tumor Suppression2▲ 18×3 topics
  38. Therapy2▲ 8.3×2 topics
  39. Targeted Therapy2▲ 7.6×3 topics
  40. Nuclear Receptors1▲ 8.6×2 topics

Which research topics does Oncolys BioPharma (Japan) publish most on?

By volume in 2022–2025: Virus-based gene therapy research, Cancer Research and Treatments, CAR-T cell therapy research and Pancreatic and Hepatic Oncology Research.

Virus-based gene therapy…3Virus-based gene therapy research: 3 fractional worksCancer Research and Trea…2Cancer Research and Treatments: 2 fractional worksCAR-T cell therapy research: 1 fractional worksPancreatic and Hepatic Oncology Research: 1 fractional worksCancer Cells and Metasta…1Cancer Cells and Metastasis: 1 fractional worksRNA Interference and Gene Delivery: 1 fractional worksImmunotherapy and Immune Responses: 0 fractional worksViral Infectious Diseases and Gene Expression in Insects: 0 fractional worksAnimal Genetics and Reproduction: 0 fractional worksCancer Genomics and Diagnostics: 0 fractional works
GeneticsBiotechnologyOncologyMolecular Biology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Virus-based gene therapy research Genetics 3 works
  2. 2 Cancer Research and Treatments Biotechnology 2 works
  3. 3 CAR-T cell therapy research Oncology 1 works
  4. 4 Pancreatic and Hepatic Oncology Research Oncology 1 works
  5. 5 Cancer Cells and Metastasis Oncology 1 works
  6. 6 RNA Interference and Gene Delivery Molecular Biology 1 works
  7. 7 Immunotherapy and Immune Responses Immunology 0 works
  8. 8 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
  9. 9 Animal Genetics and Reproduction Genetics 0 works
  10. 10 Cancer Genomics and Diagnostics Cancer Research 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available44.6%not open55.4%

World: 28% of research is openly available.

with international co-authors28.6%domestic only71.4%

World: 19% is written across borders.

How has Oncolys BioPharma (Japan)'s research output changed?

Output in 2018–2022 was 21% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Tokyo

All research institutions in Tokyo

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.